The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis

Published on Dec 1, 2019in Molecular Cancer10.68
· DOI :10.1186/s12943-019-0989-z
Lei Zhang63
Estimated H-index: 63
(CSU: Central South University),
Yiyi Liang1
Estimated H-index: 1
(CSU: Central South University)
+ 6 AuthorsFenglei Yu3
Estimated H-index: 3
(CSU: Central South University)
View in Source
Peripheral circulating free DNA (cfDNA) is DNA that is detected in plasma or serum fluid with a cell-free status. For cancer patients, cfDNA not only originates from apoptotic cells but also from necrotic tumor cells and disseminated tumor cells that have escaped into the blood during epithelial-mesenchymal transition. Additionally, cfDNA derived from tumors, also known as circulating tumor DNA (ctDNA), carries tumor-associated genetic and epigenetic changes in cancer patients, which makes ctDNA a potential biomarker for the early diagnosis of tumors, monitory and therapeutic evaluations, and prognostic assessments, among others, for various kinds of cancer. Moreover, analyses of cfDNA chromatin modifications can reflect the heterogeneity of tumors and have potential for predicting tumor drug resistance.
Figures & Tables
  • References (193)
  • Citations (3)
#1Antonia K. Roseweir (Glas.: University of Glasgow)H-Index: 11
#2Jennifer Clark (Glas.: University of Glasgow)H-Index: 2
Last.Joanne Edwards (Glas.: University of Glasgow)H-Index: 38
view all 9 authors...
3 CitationsSource
#1Jeanne Tie (WEHI: Walter and Eliza Hall Institute of Medical Research)H-Index: 19
#2Joshua D. Cohen (Johns Hopkins University)H-Index: 7
Last.Peter Gibbs (WEHI: Walter and Eliza Hall Institute of Medical Research)H-Index: 45
view all 34 authors...
33 CitationsSource
#1Jason Y. K. Chan (CUHK: The Chinese University of Hong Kong)H-Index: 12
#2Gooi Zhen (U of C: University of Chicago)H-Index: 1
Last.Nishant Agrawal (U of C: University of Chicago)H-Index: 38
view all 3 authors...
3 CitationsSource
#1Richard Mair (University of Cambridge)H-Index: 7
#2Florent Mouliere (University of Cambridge)H-Index: 15
Last.Kevin M. Brindle (University of Cambridge)H-Index: 59
view all 12 authors...
7 CitationsSource
#1Vincent Bernard (University of Texas MD Anderson Cancer Center)H-Index: 7
#2D. U. Kim (PNU: Pusan National University)H-Index: 5
Last.Hector A Alvarez (University of Texas MD Anderson Cancer Center)H-Index: 7
view all 22 authors...
24 CitationsSource
#1Sara Galimberti (UniPi: University of Pisa)H-Index: 25
#2Susanna Grassi (UNISI: University of Siena)H-Index: 6
Last.Letizia Mattii (UniPi: University of Pisa)H-Index: 17
view all 25 authors...
15 CitationsSource
#1Ben O'Leary (ICR: Institute of Cancer Research)H-Index: 8
#2Sarah Hrebien (ICR: Institute of Cancer Research)H-Index: 7
Last.Nicholas C. Turner (ICR: Institute of Cancer Research)H-Index: 45
view all 13 authors...
60 CitationsSource
#1Stephan Kruger (LMU: Ludwig Maximilian University of Munich)H-Index: 9
#2Heinemann (LMU: Ludwig Maximilian University of Munich)H-Index: 3
Last.Stefan Holdenrieder (TUM: Technische Universität München)H-Index: 18
view all 15 authors...
5 CitationsSource
#1Clara MontagutH-Index: 23
#2Joana VidalH-Index: 7
Last.Laura VisaH-Index: 13
view all 3 authors...
2 CitationsSource
#1Clare Fiala (MSH: Mount Sinai Hospital, Toronto)H-Index: 5
#2Eleftherios P. Diamandis (U of T: University of Toronto)H-Index: 99
15 CitationsSource
Cited By3
#1Erik Kouba (Medical Center of Central Georgia)
Last.Liang Cheng (IU: Indiana University)H-Index: 92
view all 12 authors...
#2Luca FalzoneH-Index: 11
Last.Aristidis M. TsatsakisH-Index: 45
view all 13 authors...
#1Rama SoundararajanH-Index: 15
#2Jared J. Fradette (University of Texas MD Anderson Cancer Center)H-Index: 3
Last.Sendurai A. ManiH-Index: 38
view all 21 authors...
2 CitationsSource